Company: XOMAP
Filing Date: 2025-12-05
Form Type: 8-K
Source: 0001193125-25-308794
Chunk: 0

Company: XOMA Royalty Corp
Filing Date: 2025-12-05
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item 2.01      Completion of Acquisition or Disposition of Assets.  

As previously disclosed, XOMA Royalty Corporation (“ XOMA”) entered into a transaction agreement, dated August 20, 2025 (the “ Transaction Agreement”), with Mural Oncology plc, a public limited company organized under the laws of Ireland (“ Mural”), and XRA 5 Corp., a Delaware corporation and wholly-owned subsidiary of XOMA (“ Merger Sub”), pursuant to which Merger Sub has agreed to acquire the entire issued and to be issued share capital of Mural (the “ Acquisition”) pursuant to an Irish High Court (the “ High Court”) sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “ Scheme”).

The High Court sanctioned the Scheme on December 3, 2025. On December 5, 2025, the Scheme and the Acquisition became effective (the “ Closing”) upon delivery of the court order to the Irish Companies Registration Office.

Pursuant to the terms of the Transaction Agreement, in connection with the Closing, Mural’s shareholders were entitled to receive a cash price of $2.035 per share (the “ Consideration”). In addition, each option to purchase Mural shares that was outstanding as of immediately prior to the Closing (whether or not vested) was, as of the Closing, automatically cancelled and converted into the right to receive an amount equal to the Consideration for each share underlying the option minus the exercise price per share for such option. Any option that had an exercise price per share that was equal to or greater than the Consideration was cancelled and ceased to be outstanding as of the Closing, and no Consideration was delivered in exchange for such options. Each restricted stock unit that was outstanding as of immediately prior to the Closing (whether or not vested) was, as of the Closing, automatically cancelled and converted into the right to receive an amount equal to the Consideration.

The foregoing descriptions of the Transaction Agreement and the transactions contemplated thereby do not purport to be complete and are qualified in their entirety by reference to the Transaction Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form8-Kand is incorporated by reference herein.